乳腺癌激素受体的表达与新辅助化疗疗效的相关性

目的 研究乳腺癌雌孕激素受体的表达与新辅助化疗疗效之间的相关性。方法 用免疫组化的方法检测46例乳腺癌患者在接受新辅助化疗之前雌孕激素受体的表达情况，新辅助化疗结束后进行疗效评价。结果 46例患者中，临床完全缓解(cCR)17例，部分缓解(PR)21例，无变化(NC)8例，其中病理完全缓解(pCR)9例，总有效率为82．6％，pCR率为19．57％。在受体双阴的22例患者中，20例有效(cCR PR)，总有效率为90．9％，NC2例；pCR6例(27．3％)，受体单阳或双阳的2，4例患者中，18例有效(cCR PR)，总有效率为75．0％，NC6例。pCR3例(12．5％)。受体双阴组患者的pCR率及总有效率都高于受体单阳或双阳组患者，但未见显著性差异。结论 受体双阴的患者可能较受体单阳或双阳的患者对化疗的敏感性更高。

Correlation of hormone receptors expression and response to neoadjuvant chemotherapy in breast cancer

Objective To study the correlation between expression of estrogen receptor(ER),expression of progesterone receptor (PR) and the response to neoadjuvant chemotherapy in breast cancer. Methods Forty-six patients with breast cancer were treated with neoadjuvant chemotherapy. ER and PR were examined immunohistochemically before chemotherapy and the response was evaluated after it. Results Seventeen patients achieved clinic complete release (cCR)and nine pathology complete release (pCR), 21 partial release (PR) and 8 no change (NC). The overall response rate was 82.6% and the pCR rate was 19.57%. Difference in response was observed between the patients with ER and PR absent and those with ER and/or PR positive tumors (90.9% vs. 75%). Pathology CR rates were also different in the two groups (27.3% vs. 12.5%), but without statistical significance. Conclusion Breast cancer with ER and PR absent may be more sensitive to neoadjuvant chemotherapy.